This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by McFadyen, M. C. E. Articles by Murray, G. I. Search for Related Content PubMed PubMed Citation Articles by McFadyen, M. C. E. Articles by Murray, G. I. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Minireview

Cytochrome P450 enzymes: Novel options for cancer therapeutics

Departments of ¹ Pathology and ² Molecular and Cell Biology, University of Aberdeen, Aberdeen, United Kingdom

Requests for Reprints: Morag C. E. McFadyen, Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, United Kingdom. Phone: 44-1224-553792; Fax: 44-1224-663002. E-mail: m.mcfadyen{at}abdn.ac.uk

The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

³ KuDOS Pharmaceuticals Web site provides detailed information in the current status of AQ4N (http://www.kudospharma.co.uk/r_d/aq4n.php; accessed September 9, 2003).

Received 9/10/03; revised 11/ 7/03; accepted 12/15/03.